Golden
Adverum Biotechnologies

Adverum Biotechnologies

Adverum is a gene therapy company committed to discovering and developing novel medicines to patients living with rare diseases and diseases of the eye.

All edits

Edits on 19 Mar 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 19 Mar 2019 10:45 pm
Edits made to:
Article (+22/-22 characters)

Article

Adverum, formerly Avalanche Biotechnologies, is a biotechnology company developing gene therapies for patients living with rare diseases and diseases of the eye that is headquartered in Menlo Park, CaliforniaMenlo Park, California and was founded in 2006 by Mark S. Blumenkranz, Mitchell H. Finer, Steven D. Schwartz, and Thomas W. Chalberg. The company officially became Adverum Biotechnologies in May, 2016 after the merger of Avalanche Biotechnologies and Annapurna Therapeutics. 

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 19 Mar 2019 10:41 pm
Edits made to:
Article (+15/-15 characters)

Article

On November 22, 2013 Adverum Biotechnologies completed a venture capitalventure capital round raising $5.7 million in capital from undisclosed investors. 

Dawson Sewell
Dawson Sewell edited on 19 Mar 2019 9:57 pm
Edits made to:
Infobox (+7/-1 properties)
Timeline (+4 events) (+789 characters)
Description (+152 characters)
Article (+1027 characters)
People (+24 cells) (+495 characters)
Further reading (+8 cells) (+361 characters)
Categories (+1 topics)
Related Topics (+1 topics)
Topic thumbnail

Adverum Biotechnologies

Adverum is a gene therapy company committed to discovering and developing novel medicines to patients living with rare diseases and diseases of the eye.

Article



Adverum, formerly Avalanche Biotechnologies, is a biotechnology company developing gene therapies for patients living with rare diseases and diseases of the eye that is headquartered in Menlo Park, California and was founded in 2006 by Mark S. Blumenkranz, Mitchell H. Finer, Steven D. Schwartz, and Thomas W. Chalberg. The company officially became Adverum Biotechnologies in May, 2016 after the merger of Avalanche Biotechnologies and Annapurna Therapeutics. 

Funding

Venture round I

On November 22, 2013 Adverum Biotechnologies completed a venture capital round raising $5.7 million in capital from undisclosed investors. 

Series B

On April 22, 2014 Adverum Biotechnologies completed their series B funding round with $55 million in capital from Venrock (lead investor), Sabby Capital, Rock Springs Capital, Redmile Group, Deerfield, and Adage Capital management. 

Venture round II

On September 7, 2014 Adverum Biotechnologies completed their second venture capital round with $10 million in funding from undisclosed investors. 

People

Name
Role
Related Golden topics

Mark S. Blumenkranz

Co-Founder



Carla Fiankan

Vice President, Regulatory Affairs



Claire Gelfman

Executive Director, Pharmaceutical Development



Jennifer Cheng

Vice President and General Council



Leone Patterson

CEO, Director, and CFO



Mehdi Gasmi

President and CSO



Michael Steel

Vice President, Quality



Mike Fitzgerald

Vice President , Human Resources



Mitchell H. Finer

Co-Founder



Pratik Jaluria

Executive Director, Process Development and Manufacturing



Steven D. Schwartz

Co-Founder



Thomas W. Chalberg

Co-Founder



Further reading

Title
Author
Link
Type

Avalanche Biotechnologies Agrees to Buy Annapurna Therapeutics

Genenews

Web

Here's Why Adverum Biotechnologies Dropped as Much as 42.4% Today

Maxx Chatsko

Web

Infobox

Categories

Related Topics

Timeline

May 7, 2016

Merger of Avalanche Biotechnologies and Annapurna Therapeutics

The company officially became Adverum Biotechnologies in May, 2016 after the merger of Avalanche Biotechnologies and Annapurna Therapeutics. 

September 19, 2014

Venture funding round II

On September 7, 2014 Adverum Biotechnologies completed their second venture capital round with $10 million in funding from undisclosed investors. 

April 22, 2014

Series B funding round

On April 22, 2014 Adverum Biotechnologies completed their series B funding round with $55 million in capital from Venrock (lead investor), Sabby Capital, Rock Springs Capital, Redmile Group, Deerfield, and Adage Capital management. 

November 2, 2013

Venture funding round I

On November 22, 2013 Adverum Biotechnologies completed a venture capital round raising $5.7 million in capital from undisclosed investor

Edits on 7 Mar 2019
Golden AI
Golden AI edited on 7 Mar 2019 10:14 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 5 Mar 2019
Henry Ogolla
Henry Ogolla approved a suggestion from Golden's AI on 5 Mar 2019 7:53 pm
Edits made to:
Infobox (+2 properties)
Henry Ogolla"Initial topic creation"
Henry Ogolla created this topic on 5 Mar 2019 7:53 pm
Edits made to:
Topic thumbnail

 Adverum Biotechnologies

Adverum is a gene therapy company committed to discovering and developing novel medicines to patients living with rare diseases and diseases of the eye.

No more activity to show.